New York, NY–(April 9, 2014) – Palladium Capital Advisors, LLC today announced that it acted as sole placement agent for AV Therapeutics, Inc. (OTCBB:AVTH) sale of common stock and five-year warrants for an aggregate purchase price of $450,000.

AV Therapeutics, Inc. (AVT) is primarily engaged in the business of developing Cancer therapeutics and immunotherapeutic vaccines that can be used together with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. Scientists at AVT have identified and patented a chemotherapeutic drug called Capridine that has shown in preclinical models to have specific activity against prostate and colon cancer. This drug is expected to be the frontline AVT product specifically in prostate cancer where no chemotherapy exists at present. The Company’s immunotherapeutics is based on the ability of certain proprietary reagents to re-educate or reprogram a failed immune system that can target previously unidentified micro-metastases. The Company intends to clinically develop both of these approaches independently specifically for prostate cancer.

The Company is conducting its research by providing funding to an academic institution(s) to conduct its research as this type of funding arrangement makes the most economic sense for start-up research. Therefore, in the future, the Company intends to expand its research efforts by identifying other promising research and funding that research through the researcher’s respective academic institution(s). The market for the Company’s products is very large. Just the drug alone and one successful vaccine against one type of cancer could result in a market potential worth billions. The proprietary technology is easily adaptable to infectious diseases enhancing the market potential several folds. The Company does not intend to market its own products. The Company intends to enter into agreements with large pharmaceutical companies whereby AVT will enjoy an upfront cash sum plus an ongoing royalty stream when the drug/vaccine(s) are approved by the FDA (Federal Drug Agency) for use in the market. The Company will search for a partner(s) in early Phase II/III clinical trials of any particular treatment modality drug and/or vaccine.

The Management of the Company believes that with a committed funding, the objective of this business plan, the first therapeutic pharmaceutical, the prostate cancer specific drug and a prostate cancer vaccine, can be evaluated through Phase I clinical trials in humans within the next 9-12 months.

For more information about the company go to: http://www.avtherapeutics.com/

For more information about the transaction see the company’s 8-K filing.